Literature DB >> 18723506

The AbetaCs of Abeta-cleaving proteases.

Malcolm A Leissring1.   

Abstract

The amyloid beta-protein (Abeta), which accumulates abnormally in Alzheimer disease (AD), is degraded by a diverse set of proteolytic enzymes. Abeta-cleaving proteases, largely ignored until only recently, are now known to play a pivotal role in the regulation of cerebral Abeta levels and amyloid plaque formation in animal models, and accumulating evidence suggests that defective Abeta proteolysis may be operative in many AD cases. This review summarizes the growing body of evidence supporting the involvement of specific Abeta-cleaving proteases in the etiology and potential treatment of AD. Recognition of the importance of Abeta degradation to the overall economy of Abeta has revised our thinking about the mechanistic basis of AD pathogenesis and identified a novel class of enzymes that may serve as both therapeutic targets and therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723506      PMCID: PMC2662051          DOI: 10.1074/jbc.R800022200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.

Authors:  E A Eckman; C B Eckman
Journal:  Biochem Soc Trans       Date:  2005-11       Impact factor: 5.407

2.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

3.  Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.

Authors:  K Vekrellis; Z Ye; W Q Qiu; D Walsh; D Hartley; V Chesneau; M R Rosner; D J Selkoe
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

4.  Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.

Authors:  Anthony R White; Tai Du; Katrina M Laughton; Irene Volitakis; Robyn A Sharples; Michel E Xilinas; David E Hoke; R M Damian Holsinger; Geneviève Evin; Robert A Cherny; Andrew F Hill; Kevin J Barnham; Qiao-Xin Li; Ashley I Bush; Colin L Masters
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

5.  Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism.

Authors:  Ke-Jie Yin; John R Cirrito; Ping Yan; Xiaoyan Hu; Qingli Xiao; Xiaoou Pan; Randall Bateman; Haowei Song; Fong-Fu Hsu; John Turk; Jan Xu; Chung Y Hsu; Jason C Mills; David M Holtzman; Jin-Moo Lee
Journal:  J Neurosci       Date:  2006-10-25       Impact factor: 6.167

Review 6.  Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease.

Authors:  C Glabe
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

7.  Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.

Authors:  H M Tucker; M Kihiko-Ehmann; S Wright; R E Rydel; S Estus
Journal:  J Neurochem       Date:  2000-11       Impact factor: 5.372

8.  Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP.

Authors:  Annelie Falkevall; Nyosha Alikhani; Shashi Bhushan; Pavel F Pavlov; Katrin Busch; Kenneth A Johnson; Therese Eneqvist; Lars Tjernberg; Maria Ankarcrona; Elzbieta Glaser
Journal:  J Biol Chem       Date:  2006-07-18       Impact factor: 5.157

9.  Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Authors:  J Steven Jacobsen; Thomas A Comery; Robert L Martone; Hassan Elokdah; David L Crandall; Aram Oganesian; Suzan Aschmies; Yolanda Kirksey; Cathleen Gonzales; Jane Xu; Hua Zhou; Kevin Atchison; Erik Wagner; Margaret M Zaleska; Indranil Das; Robert L Arias; Jonathan Bard; David Riddell; Stephen J Gardell; Magid Abou-Gharbia; Albert Robichaud; Ronald Magolda; George P Vlasuk; Thorir Bjornsson; Peter H Reinhart; Menelas N Pangalos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-16       Impact factor: 11.205

10.  Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.

Authors:  Matthew L Hemming; Michaela Patterson; Casper Reske-Nielsen; Ling Lin; Ole Isacson; Dennis J Selkoe
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

View more
  33 in total

Review 1.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Authors:  Wei-Jen Tang
Journal:  Trends Endocrinol Metab       Date:  2015-12-02       Impact factor: 12.015

2.  17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brain.

Authors:  Anusha Jayaraman; Jenna C Carroll; Todd E Morgan; Sharon Lin; Liqin Zhao; Jason M Arimoto; M Paul Murphy; Tina L Beckett; Caleb E Finch; Roberta Diaz Brinton; Christian J Pike
Journal:  Endocrinology       Date:  2012-09-07       Impact factor: 4.736

3.  Tip60 protects against amyloid-β-induced transcriptomic alterations via different modes of action in early versus late stages of neurodegeneration.

Authors:  Haolin Zhang; Bhanu Chandra Karisetty; Akanksha Bhatnagar; Ellen M Armour; Mariah Beaver; Tiffany V Roach; Sina Mortazavi; Shreya Mandloi; Felice Elefant
Journal:  Mol Cell Neurosci       Date:  2020-11-04       Impact factor: 4.314

4.  Amyloid-β Derived from the Brain of the Alzheimer's Disease Transgenic Mouse Is Resistant to Proteolytic Digestion Due to Its Conformation.

Authors:  Baian Chen; Jing Zhang; Shubo Wang; Wen Wang; Zitong Yao; Quan Sun; Yi Wu; Jing Lu
Journal:  J Mol Neurosci       Date:  2017-07-19       Impact factor: 3.444

Review 5.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

Review 7.  Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease.

Authors:  Malcolm A Leissring
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

8.  Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening.

Authors:  Christelle Cabrol; Malwina A Huzarska; Christopher Dinolfo; Maria C Rodriguez; Lael Reinstatler; Jake Ni; Li-An Yeh; Gregory D Cuny; Ross L Stein; Dennis J Selkoe; Malcolm A Leissring
Journal:  PLoS One       Date:  2009-04-22       Impact factor: 3.240

9.  Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.

Authors:  Anthony Delledonne; Naomi Kouri; Lael Reinstatler; Tomoko Sahara; Lilin Li; Ji Zhao; Dennis W Dickson; Nilufer Ertekin-Taner; Malcolm A Leissring
Journal:  Mol Neurodegener       Date:  2009-10-16       Impact factor: 14.195

10.  Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.

Authors:  Ji Zhao; Lilin Li; Malcolm A Leissring
Journal:  Mol Neurodegener       Date:  2009-01-14       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.